schliessen

Filtern

 

Bibliotheken

Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination

Botulinum neurotoxin (BoNT), a Category A biodefense agent, delivers a protease to motor neuron cytosol that cleaves one or more soluble NSF attachment protein receptors (SNARE) proteins involved in neurotransmission to cause a flaccid paralysis. No antidotes exist to reverse symptoms of BoNT intoxi... Full description

Journal Title: PloS one 2011, Vol.6(5), pp.e20352
Main Author: Kuo, Chueh-Ling
Other Authors: Oyler, George A , Shoemaker, Charles B
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1932-6203 ; PMID: 21629663 Version:1 ; DOI: 10.1371/journal.pone.0020352
Link: http://pubmed.gov/21629663
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline21629663
title: Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination
format: Article
creator:
  • Kuo, Chueh-Ling
  • Oyler, George A
  • Shoemaker, Charles B
subjects:
  • Botulinum Toxins, Type A -- Toxicity
  • Neurons -- Drug Effects
ispartof: PloS one, 2011, Vol.6(5), pp.e20352
description: Botulinum neurotoxin (BoNT), a Category A biodefense agent, delivers a protease to motor neuron cytosol that cleaves one or more soluble NSF attachment protein receptors (SNARE) proteins involved in neurotransmission to cause a flaccid paralysis. No antidotes exist to reverse symptoms of BoNT intoxication so severely affected patients require artificial respiration with prolonged intensive care. Time to recovery depends on toxin serotype because the intraneuronal persistence of the seven known BoNT serotypes varies widely from days to many months. Our therapeutic antidote strategy is to develop 'targeted F-box' (TFB) agents that target the different intraneuronal BoNT proteases for accelerated degradation by the ubiquitin proteasome system (UPS), thus promoting rapid recovery from all serotypes. These agents consist of a camelid heavy chain-only V(H) (VHH) domain specific for a BoNT protease fused to an F-box domain recognized by an intraneuronal E3-ligase. A fusion protein containing the 14 kDa anti-BoNT/A protease VHH, ALcB8, joined to a 15 kDa F-box domain region of TrCP (D5) was sufficient to cause increased ubiquitination and accelerate turnover of the targeted BoNT/A protease within neurons. Neuronal cells expressing this TFB, called D5-B8, were also substantially resistant to BoNT/A intoxication and recovered from intoxication at least 2.5 fold quicker than control neurons. Fusion of D5 to a VHH specific for BoNT/B protease (BLcB10) led to accelerated turnover of the targeted protease within neurons, thus demonstrating the modular nature of these therapeutic agents and suggesting that development of similar therapeutic agents specific to all botulinum serotypes should be readily achievable.
language: eng
source:
identifier: E-ISSN: 1932-6203 ; PMID: 21629663 Version:1 ; DOI: 10.1371/journal.pone.0020352
fulltext: fulltext
issn:
  • 19326203
  • 1932-6203
url: Link


@attributes
ID1019211084
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid21629663
sourceidmedline
recordidTN_medline21629663
sourceformatXML
sourcesystemOther
pqid869797525
galeid476891023
display
typearticle
titleAccelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination
creatorKuo, Chueh-Ling ; Oyler, George A ; Shoemaker, Charles B
ispartofPloS one, 2011, Vol.6(5), pp.e20352
identifier
subjectBotulinum Toxins, Type A -- Toxicity ; Neurons -- Drug Effects
descriptionBotulinum neurotoxin (BoNT), a Category A biodefense agent, delivers a protease to motor neuron cytosol that cleaves one or more soluble NSF attachment protein receptors (SNARE) proteins involved in neurotransmission to cause a flaccid paralysis. No antidotes exist to reverse symptoms of BoNT intoxication so severely affected patients require artificial respiration with prolonged intensive care. Time to recovery depends on toxin serotype because the intraneuronal persistence of the seven known BoNT serotypes varies widely from days to many months. Our therapeutic antidote strategy is to develop 'targeted F-box' (TFB) agents that target the different intraneuronal BoNT proteases for accelerated degradation by the ubiquitin proteasome system (UPS), thus promoting rapid recovery from all serotypes. These agents consist of a camelid heavy chain-only V(H) (VHH) domain specific for a BoNT protease fused to an F-box domain recognized by an intraneuronal E3-ligase. A fusion protein containing the 14 kDa anti-BoNT/A protease VHH, ALcB8, joined to a 15 kDa F-box domain region of TrCP (D5) was sufficient to cause increased ubiquitination and accelerate turnover of the targeted BoNT/A protease within neurons. Neuronal cells expressing this TFB, called D5-B8, were also substantially resistant to BoNT/A intoxication and recovered from intoxication at least 2.5 fold quicker than control neurons. Fusion of D5 to a VHH specific for BoNT/B protease (BLcB10) led to accelerated turnover of the targeted protease within neurons, thus demonstrating the modular nature of these therapeutic agents and suggesting that development of similar therapeutic agents specific to all botulinum serotypes should be readily achievable.
languageeng
source
version9
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/21629663$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Kuo, Chueh-Ling
1Oyler, George A
2Shoemaker, Charles B
titleAccelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination
descriptionBotulinum neurotoxin (BoNT), a Category A biodefense agent, delivers a protease to motor neuron cytosol that cleaves one or more soluble NSF attachment protein receptors (SNARE) proteins involved in neurotransmission to cause a flaccid paralysis. No antidotes exist to reverse symptoms of BoNT intoxication so severely affected patients require artificial respiration with prolonged intensive care. Time to recovery depends on toxin serotype because the intraneuronal persistence of the seven known BoNT serotypes varies widely from days to many months. Our therapeutic antidote strategy is to develop 'targeted F-box' (TFB) agents that target the different intraneuronal BoNT proteases for accelerated degradation by the ubiquitin proteasome system (UPS), thus promoting rapid recovery from all serotypes. These agents consist of a camelid heavy chain-only V(H) (VHH) domain specific for a BoNT protease fused to an F-box domain recognized by an intraneuronal E3-ligase. A fusion protein containing the 14 kDa anti-BoNT/A protease VHH, ALcB8, joined to a 15 kDa F-box domain region of TrCP (D5) was sufficient to cause increased ubiquitination and accelerate turnover of the targeted BoNT/A protease within neurons. Neuronal cells expressing this TFB, called D5-B8, were also substantially resistant to BoNT/A intoxication and recovered from intoxication at least 2.5 fold quicker than control neurons. Fusion of D5 to a VHH specific for BoNT/B protease (BLcB10) led to accelerated turnover of the targeted protease within neurons, thus demonstrating the modular nature of these therapeutic agents and suggesting that development of similar therapeutic agents specific to all botulinum serotypes should be readily achievable.
subject
0Botulinum Toxins, Type A -- Toxicity
1Neurons -- Drug Effects
general
021629663
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
310.1371/journal.pone.0020352
4MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline21629663
issn
019326203
11932-6203
rsrctypearticle
creationdate2011
addtitlePloS one
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr412011
citationpf e20352 vol 6 issue 5
startdate20110101
enddate20111231
lsr30VSR-Enriched:[galeid, pqid]
sort
titleAccelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination
authorKuo, Chueh-Ling ; Oyler, George A ; Shoemaker, Charles B
creationdate20110000
lso0120110000
facets
frbrgroupid8900046809922767567
frbrtype5
newrecords20190701
languageeng
creationdate2011
topic
0Botulinum Toxins, Type A–Toxicity
1Neurons–Drug Effects
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Kuo, Chueh-Ling
1Oyler, George A
2Shoemaker, Charles B
jtitlePlos One
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Kuo
1Oyler
2Shoemaker
aufirst
0Chueh-Ling
1George A
2Charles B
au
0Kuo, Chueh-Ling
1Oyler, George A
2Shoemaker, Charles B
atitleAccelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination
jtitlePloS one
date2011
risdate2011
volume6
issue5
spagee20352
pagese20352
eissn1932-6203
formatjournal
genrearticle
ristypeJOUR
abstractBotulinum neurotoxin (BoNT), a Category A biodefense agent, delivers a protease to motor neuron cytosol that cleaves one or more soluble NSF attachment protein receptors (SNARE) proteins involved in neurotransmission to cause a flaccid paralysis. No antidotes exist to reverse symptoms of BoNT intoxication so severely affected patients require artificial respiration with prolonged intensive care. Time to recovery depends on toxin serotype because the intraneuronal persistence of the seven known BoNT serotypes varies widely from days to many months. Our therapeutic antidote strategy is to develop 'targeted F-box' (TFB) agents that target the different intraneuronal BoNT proteases for accelerated degradation by the ubiquitin proteasome system (UPS), thus promoting rapid recovery from all serotypes. These agents consist of a camelid heavy chain-only V(H) (VHH) domain specific for a BoNT protease fused to an F-box domain recognized by an intraneuronal E3-ligase. A fusion protein containing the 14 kDa anti-BoNT/A protease VHH, ALcB8, joined to a 15 kDa F-box domain region of TrCP (D5) was sufficient to cause increased ubiquitination and accelerate turnover of the targeted BoNT/A protease within neurons. Neuronal cells expressing this TFB, called D5-B8, were also substantially resistant to BoNT/A intoxication and recovered from intoxication at least 2.5 fold quicker than control neurons. Fusion of D5 to a VHH specific for BoNT/B protease (BLcB10) led to accelerated turnover of the targeted protease within neurons, thus demonstrating the modular nature of these therapeutic agents and suggesting that development of similar therapeutic agents specific to all botulinum serotypes should be readily achievable.
doi10.1371/journal.pone.0020352
pmid21629663
oafree_for_read